7UM Stock Overview
A biotech company, develops immunotherapies against cancers in Norway. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Ultimovacs ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.18 |
| 52 Week High | NOK 14.08 |
| 52 Week Low | NOK 0.13 |
| Beta | 0.99 |
| 11 Month Change | 19.62% |
| 3 Month Change | n/a |
| 1 Year Change | -98.18% |
| 33 Year Change | -98.38% |
| 5 Year Change | -94.14% |
| Change since IPO | -94.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7UM | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 6.7% | -0.7% | 0.2% |
| 1Y | -98.2% | -17.2% | 8.5% |
Return vs Industry: 7UM underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 7UM underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 7UM volatility | |
|---|---|
| 7UM Average Weekly Movement | 21.2% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 7UM's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7UM's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 17 | Carlos de Sousa | www.ultimovacs.com |
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Ultimovacs ASA Fundamentals Summary
| 7UM fundamental statistics | |
|---|---|
| Market cap | €6.44m |
| Earnings (TTM) | -€12.94m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs 7UM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7UM income statement (TTM) | |
|---|---|
| Revenue | NOK 0 |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 0 |
| Other Expenses | NOK 149.28m |
| Earnings | -NOK 149.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -4.34 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 7UM perform over the long term?
See historical performance and comparison